0.6702

3.57% -0.0248

After Hours: .70 0.0298 +4.45%

Lineage Cell Therapeutics Inc (LCTX)

Overview News Price History Option Chain Discussions Forecast Stock Split

Lineage Cell Therapeutics Inc stock is traded at $0.6702, with a volume of 738.52K. It is down -3.57% in the last 24 hours and up +15.04% over the past month. Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also develops Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy; ReGlyde, a HyStem product in preclinical development as a device for viscosupplementation, and as a platform for intraarticular drug delivery in osteoarthritis; and Premvia, a Hystem Hydrogel product, as well as develop bone grafting products for the orthopedic diseases and injuries. In addition, it markets GeneCards, a human gene database; MalaCards, a human disease database; and Hextend, a plasma volume expander used to treat or prevent hypovolemia, including albumin, generic 6% hetastarch solutions, and crystalloid solutions, as well as undertakes various research programs for vision restoration and Demyelination. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was founded in 1990 and is headquartered in Carlsbad, California.

Previous Close:

$0.695

Open:

$0.7

24h Volume:

738.52K

Relative Volume:

0.32

Market Cap:

$152.64M

Revenue:

$8.95M

Net Income/Loss:

$-21.49M

P/E Ratio:

-5.585

EPS:

-0.12

Net Cash Flow:

$-29.24M

1W Performance:

+11.57%

1M Performance:

+15.04%

6M Performance:

-22.52%

1Y Performance:

-36.17%

1-Day Range:

$0.665

$0.71

1-Week Range:

$0.598

$0.73

52-Week Range:

$0.481

$1.61

Lineage Cell Therapeutics Inc Stock (LCTX) Company Profile

Name

Lineage Cell Therapeutics Inc

Sector

Healthcare (1183)

Industry

Biotechnology (679)

Phone

510-871-4188

Address

2173 Salk Avenue, Suite 200, Carlsbad, CA

Employee

Twitter

@LineageCell

Next Earnings Date

2024-11-07

Latest SEC Filings

LCTX's Discussions on Twitter

Compare LCTX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LCTX Lineage Cell Therapeutics Inc	0.6702	152.64M	8.95M	-21.49M	-29.24M	-0.12
VRTX Vertex Pharmaceuticals Inc	469.32	122.13B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	710.00	78.30B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	646.64	39.73B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	276.19	35.50B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	117.61	28.47B	3.30B	-501.07M	1.03B	-2.1146

Lineage Cell Therapeutics Inc Stock (LCTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-20-24	Initiated	Craig Hallum	Buy
Nov-02-22	Initiated	Robert W. Baird	Outperform
Jun-14-22	Initiated	B. Riley Securities	Buy
Aug-19-21	Initiated	Noble Capital Markets	Outperform
Mar-31-21	Initiated	Cantor Fitzgerald	Overweight

Lineage Cell Therapeutics Inc Stock (LCTX) Latest News

Feb 05, 2025

BlackRock, Inc. Increases Stake in Lineage Cell Therapeutics Inc. - GuruFocus.com

Feb 05, 2025

Stem Cell Therapy Market Types, Applications, Share, Growth - openPR

Feb 05, 2025

Feb 04, 2025

Lineage Cell Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Lifesciences Conference - BioSpace

Feb 04, 2025